AKTX
Akari TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The constructive case is that Akari has generated a steady cadence of company-source validation around PH1/AKTX-101, including AACR/ASCO preclinical visibility, WuXi XDC manufacturing support, and additional patent coverage, which could eventually attract a partner or support a rerating if the IND path firms up.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Akari is still preclinical, so the investment case depends on IND-enabling execution and future clinical entry rather than human efficacy data today [#PR-2026-06-04].
Momentum
40
Value
42
Sentiment
26
Setup hits (3d)
— · Net —
AI TargetsBase $7.50 · Bull $18.00 · Bear $3.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-26 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net —
Target $27.00
Why
Momentum40 · Δ7d -61.7
Value42 · Δ7d -0.1
Sentiment26 · Δ7d -30.6
So what
Weak posture. Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
40
26% active weight
Current posture
7d trendSoftening
Δ7d
-61.7
Δ21d
-
Value
42
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.0
Sentiment
26
34% active weight
Current posture
7d trendSoftening
Δ7d
-30.6
Δ21d
-
Why this grade
Composite grade F. Momentum 39.8 / Value 41.8 / Sentiment 26.1
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$12.6M
Beta
0.36
Shares Out
1.14M
P/E (TTM)
-
P/S (TTM)
-
P/FCF (TTM) · Derived
-31.61
Rev YoY
-
EPS YoY
+16.7%
Gross Margin
-
Op Margin
-
Net Debt
-$4.51M
Current Ratio
0.27
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology